VivoSim Receives $5M Milestone from Eli Lilly, Forecasts 500%+ Revenue Growth

VivoSim (NASDAQ:VIVS) has received a $5 million milestone payment from Eli Lilly (NYSE:LLY) tied to the advancement of a previously sold drug candidate into Phase 2 studies. The payment strengthens VivoSim's cash position, while management projects significant revenue growth fueled by expanding demand for its human-based preclinical testing platform.

Details

The milestone payment is related to a drug candidate that VivoSim previously sold to Eli Lilly, now entering Phase 2 clinical trials. VivoSim did not disclose the drug's name or additional terms of the original agreement. The payment is part of a collaboration between the two companies.

Context

VivoSim specializes in a preclinical testing platform using human cells, offering more accurate drug evaluation compared to animal models. This sector is seeing growing demand from major pharmaceutical companies like Eli Lilly, aiming to accelerate drug development and reduce costs. VivoSim's management forecasts over 500% revenue growth by fiscal year 2027, driven by an expanding customer base and increased platform usage.

What This Means for Investors

The milestone payment validates VivoSim's platform value to a leading pharma company, and the strong growth outlook reflects management's confidence in scaling the business. However, investors should monitor the company's ability to meet these projections amid competition in the preclinical testing space.